The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Adenocarcinoma
CAR T-cell therapy
CLDN6
Claudin
Esophageal cancer
Gastric cancer
Immunotherapy
Tight junctions
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
17 08 2023
17 08 2023
Historique:
received:
23
06
2023
accepted:
11
08
2023
medline:
21
8
2023
pubmed:
18
8
2023
entrez:
17
8
2023
Statut:
epublish
Résumé
The prognosis of esophageal adenocarcinoma (EAC) and gastric adenocarcinoma (GAC) remains poor, and new therapeutic approaches are urgently needed. Claudin 6 (CLDN6) is an oncofetal antigen that is largely absent in healthy tissues and upregulated in several cancers, making it a promising therapeutical target. In this study, the expression of CLDN6 was assessed in an large Caucasian EAC and GAC cohort. RNA-Seq data from 89 EACs and 371 GACs were obtained from The Cancer Genome Atlas project and EAC/GAC cases were stratified by CLDN6 mRNA expression based on a survival-associated cutoff. For groups with CLDN6 expression above or below this cutoff, differential gene expression analyses were performed using DESeq, and dysregulated biological pathways were identified using the Enrichr tool. Additionally, CLDN6 protein expression was assessed in more than 800 EACs and almost 600 GACs using a CLDN6-specific immunohistochemical antibody (clone 58-4B-2) that is currently used in Phase I/II trials to identify patients with CLDN6-positive tumors (NCT05262530; NCT04503278). The expression of CLDN6 was also correlated with histopathological parameters and overall survival (OS). EACs and GACs with high CLDN6 mRNA levels displayed an overexpression of pathways regulating the cell cycle, DNA replication, and receptor / extracellular matrix interactions. CLDN6 protein expression was associated with shorter OS in EAC and GAC, both in treatment-naïve subgroups and cohorts receiving neoadjuvant therapy. In multivariate analysis, CLDN6 protein expression was an independent adverse prognostic factor in EAC associated with a shorter OS (HR: 1.75; p = 0.01) and GAC (HR: 2.74; p = 0.028). High expression of CLDN6 mRNA is associated with the dysregulation of distinct biological pathways regulating cell growth, proliferation, and cell-matrix interactions. Clinically, the expression of CLDN6 protein is a valuable adverse prognostic marker in EAC and GAC.
Sections du résumé
BACKGROUND
The prognosis of esophageal adenocarcinoma (EAC) and gastric adenocarcinoma (GAC) remains poor, and new therapeutic approaches are urgently needed. Claudin 6 (CLDN6) is an oncofetal antigen that is largely absent in healthy tissues and upregulated in several cancers, making it a promising therapeutical target. In this study, the expression of CLDN6 was assessed in an large Caucasian EAC and GAC cohort.
METHODS
RNA-Seq data from 89 EACs and 371 GACs were obtained from The Cancer Genome Atlas project and EAC/GAC cases were stratified by CLDN6 mRNA expression based on a survival-associated cutoff. For groups with CLDN6 expression above or below this cutoff, differential gene expression analyses were performed using DESeq, and dysregulated biological pathways were identified using the Enrichr tool. Additionally, CLDN6 protein expression was assessed in more than 800 EACs and almost 600 GACs using a CLDN6-specific immunohistochemical antibody (clone 58-4B-2) that is currently used in Phase I/II trials to identify patients with CLDN6-positive tumors (NCT05262530; NCT04503278). The expression of CLDN6 was also correlated with histopathological parameters and overall survival (OS).
RESULTS
EACs and GACs with high CLDN6 mRNA levels displayed an overexpression of pathways regulating the cell cycle, DNA replication, and receptor / extracellular matrix interactions. CLDN6 protein expression was associated with shorter OS in EAC and GAC, both in treatment-naïve subgroups and cohorts receiving neoadjuvant therapy. In multivariate analysis, CLDN6 protein expression was an independent adverse prognostic factor in EAC associated with a shorter OS (HR: 1.75; p = 0.01) and GAC (HR: 2.74; p = 0.028).
CONCLUSIONS
High expression of CLDN6 mRNA is associated with the dysregulation of distinct biological pathways regulating cell growth, proliferation, and cell-matrix interactions. Clinically, the expression of CLDN6 protein is a valuable adverse prognostic marker in EAC and GAC.
Identifiants
pubmed: 37592303
doi: 10.1186/s12967-023-04433-8
pii: 10.1186/s12967-023-04433-8
pmc: PMC10436499
doi:
Substances chimiques
claudin 6
MRC5FX426I
Tight Junction Proteins
0
Claudins
0
Aminocaproic Acid
U6F3787206
Antibodies
0
Banques de données
ClinicalTrials.gov
['NCT05262530', 'NCT04503278']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
552Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Oncoimmunology. 2015 Oct 29;5(3):e1091555
pubmed: 27141353
Mol Med Rep. 2021 Sep;24(3):
pubmed: 34296304
Science. 2020 Jan 24;367(6476):446-453
pubmed: 31896660
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Gastric Cancer. 2021 Nov;24(6):1213-1226
pubmed: 34009535
Cancers (Basel). 2019 Jun 07;11(6):
pubmed: 31181620
J Exp Clin Cancer Res. 2019 Jul 17;38(1):314
pubmed: 31315643
Int J Mol Sci. 2022 Feb 12;23(4):
pubmed: 35216168
Front Oncol. 2022 Dec 22;12:1051497
pubmed: 36620607
Int J Mol Sci. 2022 Nov 12;23(22):
pubmed: 36430456
Oncol Rep. 2017 Aug;38(2):875-885
pubmed: 28656265
Nat Rev Clin Oncol. 2023 Jun;20(6):354
pubmed: 37138050
Mol Med Rep. 2018 Apr;17(4):5037-5042
pubmed: 29393423
Genome Biol. 2014;15(12):550
pubmed: 25516281
Ann Surg. 2007 Feb;245(2):241-6
pubmed: 17245177
J Exp Clin Cancer Res. 2016 Jun 21;35(1):98
pubmed: 27329034
Bioinformatics. 2019 Jun 1;35(12):2084-2092
pubmed: 30395178
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Cancer. 2020 Apr 1;146(7):1889-1901
pubmed: 31340065
Histopathology. 2012 Dec;61(6):1043-56
pubmed: 22803571
Cell Death Dis. 2019 Dec 11;10(12):949
pubmed: 31827075
Oncol Lett. 2019 May;17(5):4621-4625
pubmed: 30988820
Digestion. 2009;80(3):173-81
pubmed: 19776581
J Dig Dis. 2017 Jun;18(6):319-322
pubmed: 28509354
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Ann Surg Oncol. 2011 Apr;18(4):1195-203
pubmed: 21042944
Int J Cancer. 2014 Nov 1;135(9):2206-14
pubmed: 24710653
Prenat Diagn. 2012 Aug;32(8):742-51
pubmed: 22570279
Ann Oncol. 2021 May;32(5):609-619
pubmed: 33610734
Curr Protoc. 2021 Mar;1(3):e90
pubmed: 33780170
Front Cell Dev Biol. 2021 Aug 02;9:726656
pubmed: 34409042
J Clin Oncol. 2021 Jun 20;39(18):1995-2004
pubmed: 33891478
Ann Transl Med. 2020 Dec;8(24):1672
pubmed: 33490184
Exp Cell Res. 2017 Jan 1;350(1):226-235
pubmed: 27914788
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Gastroenterology. 2015 Aug;149(2):302-17.e1
pubmed: 25957861
Gastric Cancer. 2020 May;23(3):403-417
pubmed: 31654186
Exp Cell Res. 2020 Sep 1;394(1):112153
pubmed: 32589888